LEO Pharma Receives FDA Approval for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for Body Plaque Psoriasis

PARSIPPANY, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, today announced that the U.S. Food and Drug Administration (FDA) approved Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is a first-line single treatment now indicated for both scalp and body plaque psoriasis for up to 8 weeks.